Skip to main content

Advertisement

Log in

Immunosenescence and cancer

  • Opinion Article
  • Published:
Biogerontology Aims and scope Submit manuscript

Abstract

Age is a major risk factor for solid cancers, hitherto conventionally viewed in the context of the cell biology of carcinogenesis. However, if cancers are immunogenic, the immune system could protect against tumorigenesis (“immunosurveillance”), and vaccination or other immunomodulatory treatments should be therapeutically beneficial, as has been recently dramatically documented in a fraction of patients with certain tumors responding to immune checkpoint blockade. This begs the question that if immunity decreases with age (“immunosenescence”), this may contribute to increased cancer disease in the elderly and a lower likelihood of clinical benefit from immunotherapy. This brief review weighs up the evidence for and against a negative impact of immunosenescence on cancer control.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Download references

Acknowledgements

This study was supported by DFG PA 361-22/1.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Graham Pawelec.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pawelec, G. Immunosenescence and cancer. Biogerontology 18, 717–721 (2017). https://doi.org/10.1007/s10522-017-9682-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10522-017-9682-z

Keywords

Navigation